

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	380458	AllerG Biotic				
ARTG entry for	Medicine Listed					
Sponsor	Bio Concepts Pty Ltd					
Postal Address	PO Box 190, Bar Australia	nyo, Brisbane, QLD, 4014				
ARTG Start Date	9/12/2021					
Product Category	Medicine					
Status	Active					
Approval Area	Listed Medicines					
Conditions						

Conditions

Products

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

1. AllerG Biotic Product Type Effective Date 9/06/2022 Single Medicine Product **Permitted Indications** Maintain/support intestinal good/beneficial/friendly flora in adolescents Maintain/support intestinal good/beneficial/friendly flora Decrease/reduce/relieve symptoms of hayfever in adolescents Linked indication - Helps enhance/promote general health and wellbeing Linked indication - Maintain/support general health and wellbeing Decrease/reduce/relieve symptoms of hayfever Helps decrease/reduce/relieve symptoms of mild allergies Linked indication - Relieve eye discomfort Linked indication - Relieve itchy eyes Linked indication - Relieve eye soreness Linked indication - Decrease/reduce/relieve watery eyes/excessive lacrimation Helps decrease/reduce/relieve symptoms of mild allergies in adolescents Linked indication - Relieve itchy eyes Linked indication - Relieve eye soreness Linked indication - Decrease/reduce/relieve watery eyes/excessive lacrimation Linked indication - Relieve eye discomfort Helps decrease/reduce/relieve symptoms of mild allergies Helps decrease/reduce/relieve symptoms of mild allergies in adolescents Linked indication - Anti-inflammatory/relieve inflammation Linked indication - Helps enhance/improve/promote immune system function Helps decrease/reduce/relieve symptoms of mild allergies in children Decrease/reduce/relieve symptoms of allergic rhinitis in adolescents Decrease/reduce/relieve symptoms of allergic rhinitis Helps decrease/reduce/relieve symptoms of seasonal allergies Helps decrease/reduce/relieve symptoms of seasonal allergies in adolescents Maintain/support immune system health in adolescents Maintain/support immune system health in children Maintain/support immune system health Maintain/support healthy immune system function in adolescents Maintain/support healthy immune system function Maintain/support healthy immune system function in children

Page 1 of 2

This is not an ARTG Certificate document.



Australian Government

Department of Health

Therapeutic Goods Administration

Helps stimulate a healthy immune system response in children

Decrease/reduce/relieve skin irritation

Maintain/support skin health

Indication Requirements

Lactobacillus rhamnosus **Other Ingredients (Excipients)** colloidal anhydrous silica

microcrystalline cellulose

hypromellose magnesium stearate maize starch maltodextrin

potable water tapioca starch tricalcium phosphate

Product presentation must not imply or refer to serious allergic conditions such as anaphylaxis.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications							
No Standard Indications included on Record							
Specific Indications							
No Specific Indications included on Record							
Warnings							
No Warnings included on Record							
Additional Product information							
Pack Size/Poison information	on						
Pack Size		Poison Schedule					
Components							
1. Formulation 1							
Dosage Form	Capsule, hard						
Route of Administration	Oral						
Visual Identification							
Active Ingredients							
Bifidobacterium breve			1 billion CFU				
Bifidobacterium longum			3 billion CFU				
Lactobacillus fermentum			2 billion CFU				
Lactobacillus paracasei			5 billion CFU				

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Page 2 of 2

This is not an ARTG Certificate document.

20 billion CFU

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information